In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way Informa uses cookies please go to our Cookie Policy page.

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Court Speeds Up Apotex Appeal In Amgen Biosimilar Suit

News

Executive Summary

The US Court of Appeals for the Federal Circuit granted Apotex Inc.'s motion – or at least, in part – for an expedited appeal of a Florida court's decision to impose a preliminary injunction (PI) that prevents the firm from marketing its yet-to-be approved pegfilgrastim biosimilar until 180 days after FDA licenses the product.